PURPOSE: To assess the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), safety, and tolerability of the 24-h continuous intravenous (CIV) infusion of MK-0457, a novel pan-Aurora kinase inhibitor, in patients with advanced solid tumors and to determine the bioavailability of an oral dose of 100 mg MK-0457. STUDY DESIGN: MK-0457 was administered as a 24-h CIV infusion every 21 days. Dose escalation proceeded per toxicity criteria. A 100-mg oral dose was administered to seven patients 48 h prior to the CIV infusion dose of 64 mg/m(2)/h. RESULTS: Twenty-seven patients received a total of 86 infusions of MK-0457. Dose-limiting toxicity at 96 mg/m(2)/h included grade 4 neutropenia and grade 3 herpes zoster. The MTD was identified as 64 mg/m(2)/h. The most common adverse events were nausea, vomiting, diarrhea, and fatigue. Pharmacokinetic analyses revealed that CIV infusion MK-0457 had an estimated mean terminal half-life of approximately 6.6-10.2 h and that end-of-infusion concentrations and mean AUCs were approximately dose proportional. The estimated mean oral bioavailability of MK-0457 was 7.9%. One patient with advanced ovarian cancer attained prolonged stable disease for 11 months. CONCLUSIONS: MK-0457 was well tolerated in this schedule. Almost half the patients attained stable disease. Further development of this class of agents will likely occur in combination with other anti-cancer treatments.
PURPOSE: To assess the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), safety, and tolerability of the 24-h continuous intravenous (CIV) infusion of MK-0457, a novel pan-Aurora kinase inhibitor, in patients with advanced solid tumors and to determine the bioavailability of an oral dose of 100 mg MK-0457. STUDY DESIGN: MK-0457 was administered as a 24-h CIV infusion every 21 days. Dose escalation proceeded per toxicity criteria. A 100-mg oral dose was administered to seven patients 48 h prior to the CIV infusion dose of 64 mg/m(2)/h. RESULTS: Twenty-seven patients received a total of 86 infusions of MK-0457. Dose-limiting toxicity at 96 mg/m(2)/h included grade 4 neutropenia and grade 3 herpes zoster. The MTD was identified as 64 mg/m(2)/h. The most common adverse events were nausea, vomiting, diarrhea, and fatigue. Pharmacokinetic analyses revealed that CIV infusion MK-0457 had an estimated mean terminal half-life of approximately 6.6-10.2 h and that end-of-infusion concentrations and mean AUCs were approximately dose proportional. The estimated mean oral bioavailability of MK-0457 was 7.9%. One patient with advanced ovarian cancer attained prolonged stable disease for 11 months. CONCLUSIONS: MK-0457 was well tolerated in this schedule. Almost half the patients attained stable disease. Further development of this class of agents will likely occur in combination with other anti-cancer treatments.
Authors: Elizabeth A Harrington; David Bebbington; Jeff Moore; Richele K Rasmussen; Abi O Ajose-Adeogun; Tomoko Nakayama; Joanne A Graham; Cecile Demur; Thierry Hercend; Anita Diu-Hercend; Michael Su; Julian M C Golec; Karen M Miller Journal: Nat Med Date: 2004-02-22 Impact factor: 53.440
Authors: Yvonne G Lin; Anand Immaneni; William M Merritt; Lingegowda S Mangala; Seung Wook Kim; Mian M K Shahzad; Yvonne T M Tsang; Guillermo N Armaiz-Pena; Chunhua Lu; Aparna A Kamat; Liz Y Han; Whitney A Spannuth; Alpa M Nick; Charles N Landen; Kwong K Wong; Michael J Gray; Robert L Coleman; Diane C Bodurka; William R Brinkley; Anil K Sood Journal: Clin Cancer Res Date: 2008-09-01 Impact factor: 12.531
Authors: Gary K Schwartz; Richard D Carvajal; Rachel Midgley; Scott J Rodig; Paul K Stockman; Ozlem Ataman; David Wilson; Shampa Das; Geoffrey I Shapiro Journal: Invest New Drugs Date: 2012-06-02 Impact factor: 3.850
Authors: Guillermo Garcia-Manero; Raoul Tibes; Tapan Kadia; Hagop Kantarjian; Martha Arellano; Emily A Knight; Hao Xiong; Qin Qin; Wijith Munasinghe; Lisa Roberts-Rapp; Peter Ansell; Daniel H Albert; Brian Oliver; Mark D McKee; Justin L Ricker; Hanna Jean Khoury Journal: Invest New Drugs Date: 2015-05-02 Impact factor: 3.850
Authors: M Mita; M Gordon; N Rejeb; A Gianella-Borradori; V Jego; A Mita; J Sarantopoulos; K Sankhala; D Mendelson Journal: Target Oncol Date: 2013-07-06 Impact factor: 4.493
Authors: Jennifer R Diamond; Bruno R Bastos; Ryan J Hansen; Daniel L Gustafson; S Gail Eckhardt; Eunice L Kwak; Shuchi S Pandya; Graham C Fletcher; Todd M Pitts; Gillian N Kulikowski; Mark Morrow; Jamie Arnott; Mark R Bray; Carolyn Sidor; Wells Messersmith; Geoffrey I Shapiro Journal: Clin Cancer Res Date: 2010-12-03 Impact factor: 12.531
Authors: Shirley L Markant; Lourdes Adriana Esparza; Jesse Sun; Kelly L Barton; Lisa M McCoig; Gerald A Grant; John R Crawford; Michael L Levy; Paul A Northcott; David Shih; Marc Remke; Michael D Taylor; Robert J Wechsler-Reya Journal: Cancer Res Date: 2013-09-25 Impact factor: 12.701